Human CYP2B6: expression, inducibility and catalytic activities

被引:218
作者
Gervot, L
Rochat, B
Gautier, JC
Bohnenstengel, F
Kroemer, H
de Berardinis, V
Martin, H
Beaune, P
de Waziers, I
机构
[1] Univ Paris 05, INSERM, U490, F-75270 Paris 06, France
[2] Univ Kansas, Simons Lawrence, KS USA
[3] Nestle Res Ctr, CH-1000 Lausanne, Switzerland
[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany
[5] CNRS, Ctr Genet Mol, Gif Sur Yvette, France
[6] CRVA Rhone Poulenc Rorer, Serv Toxicol Expt, Vitry Sur Seine, France
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP2B6; heterologous expression; tissue expression; inducibility;
D O I
10.1097/00008571-199906000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human cytochrome (CYP)2B6 cDNA was cloned and expressed in bacteria and in yeast. Its expression in Saccharomyces cerevisiae enabled us to obtain, at a high level, an active yeast-expressed CYP2B6 protein, so as to assess its role in the metabolism of ethoxyresorufin, pentoxyresorufin, benzyloxyresorufin, ethoxycoumarin, testosterone and cyclophosphamide, Kinetic analysis showed that human CYP2B6 preferentially metabolized benzyloxyresorufin and pentoxyresorufin, although other CYPs also metabolized these substrates in human liver microsomes. CYP2B6 also manifested a strong 4-hydroxycyclophosphamide activity. Its expression in Escherichia coli enabled us to produce a very specific anti-human CYP2B6 antibody. No cross reactivity of this antibody was observed with CYPs1A1, 1A2, 3A4, 3A5, 2C8, 2C9, 2C18, 2C19, 2D6 or 2E1. This antibody enabled us to study the hepatic and extrahepatic expression of CYP2B6 in man, as well as its expression and inducibility in primary cultured human hepatocytes and in different human cell lines. Immunoblot analysis revealed that the CYP2B6 protein was expressed in 43 of the 48 human liver samples tested, with levels ranging from 0.4 to 8 pmol/mg of microsomal protein with a mean of 1.7 pmol/mg protein, CYP2B was also expressed in human brain, intestine and kidney, and at a lower level in the lung. CYP2B mRNA was detected in human liver, kidney, lung, trachea and intestine, We also found that CYP2B6 is induced at protein and mRNA levels by phenobarbital (2 mM) and cyclophosphamide (1 mM), an anticancer drug known to be metabolized by CYP2B6, No expression or inducibility of CYP2B6 was observed in any of the human cell lines tested, Pharmacogenetics 9:295-306 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:295 / 306
页数:12
相关论文
共 56 条
  • [41] Yeast expression of animal and plant P450s in optimized redox environments
    Pompon, D
    Louerat, B
    Bronine, A
    Urban, P
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 51 - 64
  • [42] CDNA CLONING AND FUNCTIONAL EXPRESSION IN YEAST SACCHAROMYCES-CEREVISIAE OF BETA-NAPHTHOFLAVONE-INDUCED RABBIT LIVER P-450-LM4 AND P-450-LM6
    POMPON, D
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 177 (02): : 285 - 293
  • [43] XENOBIOTIC METABOLISM IN HUMAN-BRAIN - PRESENCE OF CYTOCHROME-P-450 AND ASSOCIATED MONO-OXYGENASES
    RAVINDRANATH, V
    ANANDATHEERTHAVARADA, HK
    SHANKAR, SK
    [J]. BRAIN RESEARCH, 1989, 496 (1-2) : 331 - 335
  • [44] MEASUREMENT OF ENZYME-ACTIVITIES OF CYTOCHROME-P-450 ISOENZYMES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF PRODUCTS
    REINERINK, EJM
    DOORN, L
    JANSEN, EHJM
    VANIERSEL, AAJ
    [J]. JOURNAL OF CHROMATOGRAPHY, 1991, 553 (1-2): : 233 - 241
  • [45] EXPRESSION OF HUMAN LIVER CYTOCHROME-P450 IIIA4 IN YEAST - A FUNCTIONAL-MODEL FOR THE HEPATIC ENZYME
    RENAUD, JP
    CULLIN, C
    POMPON, D
    BEAUNE, P
    MANSUY, D
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 194 (03): : 889 - 896
  • [46] PURIFICATION AND CHARACTERIZATION OF HEPATIC-MICROSOMAL CYTOCHROME-P-450
    RYAN, DE
    LEVIN, W
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 45 (02) : 153 - 239
  • [47] Sambrook J, 1989, MOL CLONING LAB MANU
  • [48] SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254
  • [49] REPEATED HIGH-DOSE CYCLOPHOSPHAMIDE ADMINISTRATION IN BONE-MARROW TRANSPLANTATION - EXPOSURE TO ACTIVATED METABOLITES
    SCHULER, U
    EHNINGER, G
    WAGNER, T
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 20 (03) : 248 - 252
  • [50] SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414